Results 111 to 120 of about 4,636,683 (298)

PALLIATION AND LIFE QUALITY IN LUNG-CANCER - HOW GOOD ARE CLINICIAN AT JUDGING TREATMENT OUTCOME [PDF]

open access: yes, 1991
A recent trial by the MRC Lung Cancer Working Party used physician assessments to compare two palliative schedules of radiotherapy in lung cancer.
Yarnold, J   +7 more
core   +1 more source

Castration‐resistant prostate cancer cells are addicted to the high activity of cyclin‐dependent kinase 2

open access: yesMolecular Oncology, EarlyView.
We show that emergence of castration‐resistant prostate (CRPC) is associated with significant upregulation of cyclins that positively regulate cyclin‐dependent kinase 2 (CDK2) and concomitant downregulation of CDK4 cyclins. This renders CRPC cells dependent on the high activity of CDK2, and CDK2 inhibitors synergistically sensitize CRPC cells to both ...
Joyeeta Chatterjee   +3 more
wiley   +1 more source

Risk factors for primary lung cancer among never smokers by gender in a matched case-control study

open access: yes, 2014
Lung cancers that occur in never smokers differ from those that occur in smokers. We performed an analysis of potential epidemiological risk factors for lung cancer among never smokers.
Lo, Yen-Li;Hsiao, Chin-Fu;Chang, Gee-Chen;Tsai, Ying-Huang;Huang, Ming-Shyan;Su, Wu-Chou;Chen, Yuh-Min;Hsin, Che-Wei;Chang, Chin-Hao;Yang, Pan-Chyr;Chen, Chien-Jen;Hsiung, Chao A.   +1 more
core  

Mesenchymal stem cells as vectors for lung cancer therapy [PDF]

open access: yes, 2013
Despite recent advances in treatment, lung cancer accounts for one third of all cancer-related deaths, underlining the need of development of new therapies.
Laurent, GJ, Janes, SM, Kolluri, KK
core  

Unraveling the epigenetic code in cancer cell–tumor microenvironment crosstalk

open access: yesMolecular Oncology, EarlyView.
Epigenetic regulation is a key driver of cancer development and progression. Diverse epigenetic alterations in cancer cells and components of the tumor microenvironment (TME) orchestrate their communication through multiple mechanisms. We discuss how the epigenetic code coordinates bidirectional cancer cell–TME crosstalk to promote cancer progression ...
Ji Hoon Park, Mi‐Young Kim
wiley   +1 more source

Arginine methylation as a regulatory ratchet in cancer: From substrate selection to malignant‐state stabilization

open access: yesMolecular Oncology, EarlyView.
Arginine methylation can be viewed as a persistence‐prone post‐translational modification regulated by a network of PRMTs. Competitive and compensatory interactions among PRMTs can redistribute methylation across substrate pools shaped by sequence, structural, spatial, and environmental layers, reinforcing RNA‐processing, chromatin, and signaling ...
So Hyun Kwon, Ji Min Lee
wiley   +1 more source

Lung cancer screening programs [PDF]

open access: yes
CDC funds states, tribes, U.S. Affiliated Pacific Islands, and territories through the National Comprehensive Cancer Control Program (NCCCP) to form or support coalitions to fight cancer in their communities. The purpose of this report is to describe how

core  

Cigarette-Specific Carcinogen Induces Stabilization of DNA methyltransferases through AKT/GSK3β/βTrCP Pathway in Lung Cancer [PDF]

open access: yes, 2011
[[abstract]]Background: Most lung cancer cases are caused by cigarette-specific carcinogens, such as nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Previous studies have shown that NNK induces promoter hypermethylation of several tumor
Yi-Shuan Hsieh, 謝翊萱
core  

Multifunctional role of PED/PEA15 in cell death and cell motility in human non small cell lung cancer (NSCLC) [PDF]

open access: yes, 2009
PED (phosphoprotein enriched in diabetes) is a 15 KDa protein involved in many cellular pathways and human diseases, including type II diabetes and cancer. We recently reported its overexpression in breast and lung cancers, and B-cell chronic lymphocytic
Zanca, Ciro
core   +1 more source

Lung Cancer [PDF]

open access: yesPET Clinics, 2018
Gang, Cheng, Tim, Akhurst
openaire   +2 more sources

Home - About - Disclaimer - Privacy